Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

Bioverativ, Bicycle Therapeutics Partner to Develop Sickle Cell Disease Therapeutics

Two pharmaceutical companies, Bioverativ and Bicycle Therapeutics, have agreed to jointly discover, develop and market novel therapies for sickle cell disease (SCD) and hemophilia. The $10 million accord seeks to identify and develop therapeutic molecules based on Bicycle’s bicyclic peptide product platform to treat rare blood disorders. This new modality combines attributes…

Sickle Cell Disease Association of America Receives $11.6 Million Grant for Follow–Up Services

The Health Resources and Services Administration (HRSA), part of the U.S. Department of Health and Human Services, has awarded the Sickle Cell Disease Association of America (SCDAA) a $2.9 million annual grant for the next four years to establish a national infrastructure to ensure sickle cell disease (SCD) patients receive appropriate follow–up care…